Evaluating the Anesthetic Potency and Recovery Time of Remimazolam Tosilate vs. Remimazolam Besylate in Outpatient Hysteroscopic Procedures

Abstract

Remimazolam is a novel ultra-short-acting benzodiazepine with increasing use in ambulatory surgical procedures due to its rapid onset and recovery profile. This study aims to compare the anesthetic potency and recovery time of remimazolam tosilate and remimazolam besylate in outpatient hysteroscopic procedures. A randomized controlled trial was conducted on 150 patients undergoing elective hysteroscopy, with participants receiving either remimazolam tosilate or remimazolam besylate as the primary sedative agent. The primary outcomes included induction time, depth of sedation, and recovery time, while secondary outcomes assessed hemodynamic stability, postoperative adverse effects, and patient satisfaction. The results showed that both formulations provided effective sedation with rapid onset; however, remimazolam tosilate demonstrated a slightly shorter recovery time and faster clearance, making it more suitable for outpatient procedures. Hemodynamic parameters remained stable in both groups, and no significant differences in adverse effects were observed. The study concludes that remimazolam tosilate offers a marginal advantage over remimazolam besylate in terms of recovery time, which may be beneficial in fast-track outpatient settings. Further studies with larger sample sizes are recommended to confirm these findings and refine dosing strategies for optimal clinical outcomes